-
Featured Authors
-
Archives
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: February 2011
Release of BIO/Biomedtracker Drug Approval Rates Study
BIO and BioMedTracker are pleased to present the findings of their joint clinical trial success rates study. Using clinical trial data from the past seven years, this analysis examines the most recent probability of success by treatment type, phase of development and therapeutic area. The overall success rate for drugs moving through clinical trials to FDA approval from late 2003 to the end of 2010 is near one in 10, not one in five to one Read More >
WSJ: “Patent Office to Get a Boost”
An article from the Wall Street Journal regarding the Adminstration’s budget proposal for the Patent Office. Highlights: WASHINGTON—The Obama administration’s budget blueprint for fiscal 2012 seeks to boost the speed and quality of services of the U.S. Patent and Trademark Office, including through the use of temporary surcharges on patent fees. The Obama administration said the fee surcharge, along with regulatory and legislative reforms, would provide the Patent Office with $2.7 billion in resources in Read More >
Getting Comparative Effectiveness Research Right Means Making It Patient-Centered
I have had epilepsy since I was fifteen. Back in the 1950s many people—my parents included— believed that my “fits” were caused by a spiritual force. Growing up with this neurological disorder and dealing with the misinformation surrounding its causes and treatment was difficult. My disability also got me kicked out of seminary. Fortunately, since then, the world has changed for the better for those of us with disabilities. It wasn’t until I was a Read More >
Coexistence Depends on Neighbors
Capital Press wrote an editorial for their February 10 edition about the recent USDA decisions on alfalfa and sugar beets. Secretary of Agriculture Tom Vilsack has spent the past several months playing Solomon, seeking to split the difference between farmers who want to grow Roundup Ready alfalfa and organic growers who say the crop puts their livelihood at risk. USDA’s Animal and Plant Health Inspection Service recently completed a court-ordered environmental impact statement on Roundup Read More >
Role of Public-Sector Research in the Discovery of Drugs and Vaccines
Interesting article out of the New England Journal of Medicine entitled The Role of Public-Sector Research in the Discovery of Drugs and Vaccines. Findings: We found that during the past 40 years, 153 new FDA-approved drugs, vaccines, or new indications for existing drugs were discovered through research carried out in PSRIs [public-sector research institutions]. These drugs included 93 small-molecule drugs, 36 biologic agents, 15 vaccines, 8 in vivo diagnostic materials, and 1 over-the-counter drug. More Read More >
